<DOC>
	<DOC>NCT00089479</DOC>
	<brief_summary>This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer. Following 4 cycles of Adriamycin and Cytoxan, patients will be randomized to receive either 1)Taxotere 75mg/m2 iv on day 1 and Xeloda 825mg/m2 po bid on days 1-14 of each 3 week cycle or 2) Taxotere 100mg/m2 iv alone on day 1 of each 3 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>female patients 1870 years of age; adenocarcinoma of the breast; previous invasive breast cancer if diagnosed &gt;5 years before entering study; no evidence of metastatic disease. history of severe hypersensitivity reaction to Taxotere; previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; treatment with fluoropyrimidine (5fluorouracil) within the last 5 years.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>